Vanguard Group Inc lifted its position in Arcus Biosciences Inc (NYSE:RCUS) by 2.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 452,409 shares of the company’s stock after acquiring an additional 12,511 shares during the period. Vanguard Group Inc’s holdings in Arcus Biosciences were worth $6,307,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Schwab Charles Investment Management Inc. bought a new position in shares of Arcus Biosciences in the 2nd quarter worth approximately $491,000. Marshall Wace LLP purchased a new stake in shares of Arcus Biosciences in the 3rd quarter worth approximately $247,000. Platinum Investment Management Ltd. grew its stake in shares of Arcus Biosciences by 81.4% in the 3rd quarter. Platinum Investment Management Ltd. now owns 95,841 shares of the company’s stock worth $1,336,000 after buying an additional 43,000 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Arcus Biosciences by 84.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 472,072 shares of the company’s stock worth $6,581,000 after buying an additional 215,534 shares during the last quarter. Finally, BlackRock Inc. grew its stake in shares of Arcus Biosciences by 29.9% in the 3rd quarter. BlackRock Inc. now owns 435,424 shares of the company’s stock worth $6,069,000 after buying an additional 100,154 shares during the last quarter. 39.19% of the stock is owned by hedge funds and other institutional investors.

Shares of Arcus Biosciences stock remained flat at $$10.81 during midday trading on Monday. The company had a trading volume of 937 shares, compared to its average volume of 80,036. Arcus Biosciences Inc has a 52 week low of $8.57 and a 52 week high of $22.10.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Thursday, November 8th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.13. The company had revenue of $4.29 million during the quarter, compared to analysts’ expectations of $1.40 million. As a group, analysts forecast that Arcus Biosciences Inc will post -2.04 earnings per share for the current fiscal year.

In related news, President Juan C. Jaen purchased 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 13th. The shares were bought at an average price of $11.80 per share, for a total transaction of $118,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Separately, Zacks Investment Research upgraded Arcus Biosciences from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Tuesday, January 15th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Arcus Biosciences has an average rating of “Buy” and a consensus price target of $18.00.

TRADEMARK VIOLATION WARNING: This story was reported by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody.

See Also: What is a back-end load?

Want to see what other hedge funds are holding RCUS? Visit to get the latest 13F filings and insider trades for Arcus Biosciences Inc (NYSE:RCUS).

Institutional Ownership by Quarter for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with's FREE daily email newsletter.